NanoEcho has chosen the supplier Vermon SA, and started cooperation for the development and future manufacturing of the ultrasound transducer.
As an important step in NanoEchos work, to design and produce a product for commercial use, NanoEcho will collaborate with Vermon in the development of the ultrasound transducer.
NanoEcho and Vermon have signed a Letter of intent, regarding collaboration of an ultrasound transducer integrated in a rectal probe, which utilizes NanoEcho’s patented magnetomotive ultrasound technology. The probe is aimed to be used at hospitals, as support in rectal cancer diagnostics and will be CE-marked according to the EU Medical Device Regulation.
In NanoEcho’s next step, development of a commercial product, Vermon will be one of the key suppliers. Together with Vermon, NanoEcho will develop an ultrasound transducer optimized to fulfill both market, manufacturing and regulatory requirements of a commercial medical device.
Vermon, an International OEM Leading Manufacturer provides ultrasound technologies and solutions for the medical device industry. Vermon Headquarters are in Tours, France, and are certified under ISO 13485 and ISO 14001 Quality Management Systems. Vermon has a long-term market experience in development of applications of ultrasound probes at a global scale.
We are very pleased to have Vermon on board as a supplier in the next step of our journey. Their expertise of both development and manufacturing of innovative ultrasound probes will bring a solid foundation to our design of a commercial product. The team is very eager to get started and we have planned several joint activities within the near future, says Linda Persson, CEO for NanoEcho.
If you have any questions, please contact
Kristina Hallström, CMO & CCO
e-mail: ir@nanoecho.se
NanoEcho develops a new technology for clearer diagnostics of, as the first phase, rectal cancer. The imaging technology is based on a new medical approach where nanotechnology is used in combination with modern ultrasound technology. The images that are generated are intended to facilitate differentiation between healthy and diseased tissue and at the same time determine the location of the cancer tissue more precisely. The aim is to provide more precise, simpler, and less costly diagnosis of cancers and other diseases. With clearer diagnostics, the company wants to assist treating physicians with better guidance for more personalized treatment. Both the quality of life of the patients and their chance of survival can improve after treatment, with reduced treatment costs. www.nanoecho.se
